

@article {8225,
	title = {{Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection.}},
	journal = {BioMed Research International},
	volume = {2014},
	year = {2014},
	pages = {158520},
	publisher = {Hindawi Publishing Corporation},
	abstract = {<p>The resistance rates of Helicobacter pylori to amoxicillin and metronidazole therapy are higher in eastern Taiwan as compared to national and worldwide rates. The high resistance rate in this territory justified a search for a better eradication regimen. We conducted an open-labeled, prospective, randomized, and controlled study in a tertiary referral hospital in eastern Taiwan. Between December 2007 and December 2009, a total of 153 Helicobacter pylori-positive, therapy-na\&iuml;ve patients with a positive rapid urease test were recruited for random assignment to two seven-day treatment groups: levofloxacin (500 mg), amoxicillin/clavulanate (875 mg/125 mg), and rabeprazole (20 mg) twice per day (LAcR) or clarithyromicin (500 mg), amoxicillin (1000 mg), and rabeprazole (20 mg) twice per day (CAR). Helicobacter pylori eradication was assessed using the (13)C-urea breath test or rapid urease test performed at least 4 weeks after the end of treatment. After exclusion, 146 patients were enrolled and allocated in the study. The Helicobacter pylori eradication rates analyzed by both intention to treat (78.1{\%} versus 57.5{\%</p>
},
	keywords = {Amoxicillin, Amoxicillin: administration {\&} dosage, Bacterial, Bacterial: drug effects, Bacterial: genetics, Clavulanic Acid, Clavulanic Acid: administration {\&} dosage, Drug Combinations, Drug Resistance, Female, Helicobacter Infections, Helicobacter Infections: drug therapy, Helicobacter Infections: genetics, Helicobacter Infections: pathology, helicobacter pylori, Helicobacter pylori: drug effects, Helicobacter pylori: genetics, Helicobacter pylori: pathogenicity, Humans, Levofloxacin, Levofloxacin: administration {\&} dosage, Male, Rabeprazole, Rabeprazole: administration {\&} dosage},
	issn = {2314-6141},
	doi = {10.1155/2014/158520},
	url = {http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4066685{\&}tool=pmcentrez{\&}rendertype=abstract},
	author = {Ming C Chen and Wei Y Lei and Jen S Lin and Chih H Yi and Deng C Wu and Chi T Hu}
}
